Paroxysmal Nocturnal Hemoglobinuria
Final Evidence Report & Meeting Summary
Fahim SM, Makam AN, Suh K, Carlson JJ, Richardson M, Herce-Hagiwara B, et al. Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria. J Manag Care Spec Pharm. 2024;30(6):618-23. doi: 10.18553/jmcp.2024.30.6.618. PubMed PMID: 38824627; PubMed Central PMCID: PMC11145001.
Chronic Obstructive Pulmonary Disease
Final Evidence Report and Meeting Summary
Anemia in Myelodysplastic Syndrome
Final Evidence Report and Meeting Summary
Fahim SM, Tice JA, Luu L, Carlson JJ, Richardson M, Herce-Hagiwara B, et al. Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum. J Manag Care Spec Pharm. 2024;30(12):1479-85. doi: 10.18553/jmcp.2024.30.12.1479. PubMed PMID: 39612256; PubMed Central PMCID: PMC11607211.
Anemia in Chronic Kidney Disease
Final Evidence Report & Meeting Summary
Mustafa RA, Bloudek L, Fox G, Carlson JJ, Campbell JD, Agboola F, Pearson SD, Rind DM. Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value; Final Evidence Report. Institute for Clinical and Economic Review, March 5, 2021. https://icer.org/assessment/anemia-in-chronic-kidney-disease-2021/#timeline.
Amyotrophic Lateral Sclerosis (ALS)
Final Evidence Report and Meeting Summary
Nikitin D, Makam AN, Suh K, et al. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. Feb 2023;29(2):216-221. doi:10.18553/jmcp.2023.29.2.216
Non-Alcoholic Steatohepatitis
Fahim SM, Tice JA, Suh K, Carlson JJ, Richardson M, Chu JN, et al. Resmetirom for nonalcoholic steatohepatitis. J Manag Care Spec Pharm. 2023;29(10):1169-72. doi: 10.18553/jmcp.2023.29.10.1169.
Metachromatic Leukodystrophy
Final Evidence Report and Meeting Summary
Fahim SM, Lin G, Suh K, Carlson JJ, Richardson M, Herce-Hagiwara B, et al. Atidarsagene autotemcel for metachromatic leukodystrophy. J Manag Care Spec Pharm. 2024;30(2):201-5. doi: 10.18553/jmcp.2024.30.2.201. PubMed PMID: 38308621; PubMed Central PMCID: PMC10838137.
Non-Small Cell Lung Cancer
Final Evidence Report and Meeting Summary
Chemotherapy-Induced Neutropenia
Ulcerative Colitis
Final Evidence Report & Meeting Summary
Pandey R, Ollendorf DA, Fazioli K, Bloudek L, Carlson JJ, Pearson SD. The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis. J Manag Care Spec Pharm. 2021;27(3):405-10. doi: 10.18553/jmcp.2021.27.3.405. PubMed PMID: 33645245; PubMed Central PMCID: PMC10391273.
Bloudek LM, Pandey R, Fazioli K, Ollendorf DA, Carlson JJ. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis. J Manag Care Spec Pharm. 2021;27(8):1046-55. doi: 10.18553/jmcp.2021.27.8.1046. PubMed PMID: 34337994; PubMed Central PMCID: PMC10390993.
Hereditary Angioedema
2021 RWE UPDATE: Final Updated Assessment
2018 Final Evidence Report & Meeting Summary
Jaksa A, Bloudek L, Carlson JJ, Shah K, Chen Y, Patrick AR, et al. Key learnings from Institute for Clinical and Economic Review’s real-world evidence reassessment pilot. Int J Technol Assess Health Care. 2022;38(1):e32. Epub 20220314. doi: 10.1017/S0266462322000162. PubMed PMID: 35357284.
Agboola F, Lubinga S, Carlson JJ, Lin GA, Dreitlein WB, Pearson SD. The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks. J Manag Care Spec Pharm. 2019;25(2):143-8.
Prostate Cancer
Final Evidence Report & Meeting Summary
Opioid Epidemic: Supervised Injection Facilities
Peanut Allergy:
Diabetes: Type 2
2022: Final Evidence Report and Meeting Summary
2019: Public Comments on Draft Evidence Report
Heme A:
Final Evidence Report & Meeting Summary
Atopic Dermatitis:
2021: Final Evidence Report and Meeting Summary
2017: Atopic Dermatitis: Final Report
Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. J Manag Care Spec Pharm. 2022 Jan;28(1):108-114. doi: 10.18553/jmcp.2022.28.1.108. PubMed PMID: 34949111.
Multiple Myeloma:
Multiple Myeloma: Final Evidence Report and Meeting Summary
Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapsed/refractory Multiple Myeloma in the U.S. Journal of Managed Care & Specialty Pharmacy. 2017 (In Press).
Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapse/refractory multiple myeloma in the US. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA.
Multiple Sclerosis:
Multiple Sclerosis: Final Evidence Report
Synnott PG, Bloudek LM, Sharaf R, Carlson JJ, Pearson SD. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis. J Manag Care Spec Pharm. 2020;26(3):236-9. doi: 10.18553/jmcp.2020.26.3.236. PubMed PMID: 32105176; PubMed Central PMCID: PMC9476233.
Brouwer E, Carlson JJ, Zimmermann M. Drug-specific discontinuation rates for available multiple sclerosis treatments. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA.
Strand L, Zimmermann M, Carlson JJ, Hansen RN. Cost-utility of early versus delayed treatment with interferon beta-1b in clinically isolated syndrom (CIS) from a United States (US) payer perspective. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA.
Zimmermann M, Brouwer E, Tice JA, et al. Cost-utility of disease modifying therapies for relapsing-remitting multiple sclerosis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA.
Osteoporosis:
Osteoporosis: Final Evidence Report
Psoriasis:
Psoriasis: Final Evidence Report and Meeting Summary
Hendrix N, Ollendorf DA, CHapman R, et al. Cost-effectiveness of targeted therapy for moderate-to-severe plaque psoriasis: an analysis based on an institute for clinical and economic review (ICER) report. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA.
Inherited Retinal Disease:
Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson JJ. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. Value Health. 2019;22(2):161-7. doi: 10.1016/j.jval.2018.09.2841. PubMed PMID: 30711060.